Tumor size, treatment patterns, and survival in neuro-oncology patients before and during the COVID-19 pandemic
Authors:
Open Access
- 6 September 2023
- journal article
- review article
- Published by Springer Nature in Neurosurgical Review
- Vol. 46 (1) , 1-10
Abstract
The COVID-19 pandemic has disrupted healthcare delivery worldwide, leading to significant delays in cancer diagnosis and treatment. This study aimed to investigate the impact of the pandemic on the diagnosis and treatment of malignant brain tumors, specifically glioblastoma (GBM) and cerebral metastasis (CM), in a specialized neuro-oncology center. We analyzed data from 236 patients diagnosed with previously unknown malignant brain tumors between January 2018 and December 2021. Patients were classified into two groups: pre-COVID (January 2018 to December 2019) and COVID (January 2020 to December 2021). Tumor volumes were compared between the two groups and factors affecting tumor volumes were studied. Of 236 patients diagnosed with previously unknown malignant brain tumors, 114 were in the pre-COVID group and 122 were in the COVID group. Median tumor volumes at first diagnosis were significantly larger in the COVID group compared to the pre-COVID group (21.7 vs 15.7 cm3; p < 0.05). The survival times for the overall cohort and the GBM and CM subgroups did not differ significantly between the pre-COVID and COVID periods. Delays in diagnosis and treatment during the COVID-19 pandemic led to larger tumor volumes at diagnosis for patients with malignant brain tumors. However, these larger tumors did not result in worse survival outcomes. This counterintuitive finding highlights the crucial role of specialized neuro-oncological centers in mitigating the potential negative impact of delayed treatment and emphasizes the need for continued access to specialized care during times of crisis.Keywords
Funding Information
- Universitätsklinikum Jena
This publication has 28 references indexed in Scilit:
- Response Assessment in Neuro-Oncology Criteria for Gliomas: Practical Approach Using Conventional and Advanced TechniquesAmerican Journal of Neuroradiology, 2019
- Supratotal Resection of Glioblastoma: Is Less More?2019
- Surgery for Glioblastoma in Light of Molecular Markers: Impact of Resection and MGMT Promoter Methylation in Newly Diagnosed IDH-1 Wild-Type GlioblastomasNeurosurgery, 2018
- The impact of surgery in molecularly defined low-grade glioma: an integrated clinical, radiological, and molecular analysisNeuro-Oncology, 2017
- Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC·3): a multicentre, randomised, controlled, phase 3 trialThe Lancet Oncology, 2017
- Short-Course Radiation plus Temozolomide in Elderly Patients with GlioblastomaNew England Journal of Medicine, 2017
- Surgery of highly eloquent gliomas primarily assessed as non-resectable: risks and benefits in a cohort studyBMC Cancer, 2013
- The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studiesJournal of Clinical Epidemiology, 2008
- Role of Extent of Resection in the Long-Term Outcome of Low-Grade Hemispheric GliomasJournal of Clinical Oncology, 2008
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005